BeOne Medicines AG (HKG:6160)
189.80
-2.20 (-1.15%)
At close: Dec 10, 2025
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.41B USD in the quarter ending September 30, 2025, with 41.00% growth. This brings the company's revenue in the last twelve months to $4.97B, up 50.43% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.97B
Revenue Growth
+50.43%
P/S Ratio
7.09
Revenue / Employee
$452.06K
Employees
11,000
Market Cap
274.43B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
| WuXi XDC Cayman | 5.58B |
BeOne Medicines AG News
- 4 weeks ago - BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M - Seeking Alpha
- 5 weeks ago - BeiGene Q3 2025 Earnings Preview - Seeking Alpha
- 3 months ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 4 months ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 4 months ago - BeiGene's Earnings: A Preview - Benzinga
- 4 months ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 6 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 6 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn